| Name | Title | Contact Details |
|---|---|---|
Michael Corbett |
Associate Vice President, IS Infrastructure and Operations | Profile |
April Giard |
Vice President and Chief Information Officer | Profile |
With 15,000 employees across 50 states, HealthChannels provides everything your practice needs to revolutionize how healthcare is delivered. What started as the nation`s most-used medical scribe company has grown into a group of three distinct, highly-specialized companies; ScribeAmerica, CareThrough, and QueueLogix. Together, these “channels” enable providers to improve clinical outcomes by providing highly-skilled clerical support for EMR documentation, patient engagement, medical coding and so much more.
Cleveland Area Hospital is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cleveland, OK. To find more information about Cleveland Area Hospital, please visit www.clevelandareahospital.com
Boston Medical Center Health Plan Inc is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Technology Commercialization Group is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.